The collaborative effort put in place for the LUNG Master Protocol is a game changing process. It will revolutionize the way clinical trials are conducted, leading the way to more rapid drug development and approval for patients. For the first time, a biomarker-driven lung cancer clinical trial will begin with the patient as the focus of the trial, and personalizing therapy to the specific mutations in their tumor, unlike the traditional method of focusing on the drug and testing who responds to it. This unprecedented public-private partnership will drive us closer to the precision medicine era where each patient gets personalized therapy for their disease, instead of blanket therapy that might not be the right treatment of choice for them, boosting survival and saving more lives.
-Bonnie J. Addario, Founder and Chair, Addario Lung Cancer Foundation